The company has obtained the first set of positive results of PK study with new oral formulation of Beleodaq® PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the first set of positive results from a preclinical pharmacokinetic (PK) study on the bioavailability of an oral formulation of belinostat (Beleodaq®) and the next steps in its development plan for the new formulation. Beleodaq® is a histone deacetylase inhibitor (HDACi) currently approved in the US for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The current formulation of belinostat is a lyophilized formulation for intravenous (IV) use. The aim of the company is to develop an oral formulation of belinostat offering strong benefits for patients and physicians in terms of compliance, as well as opening new opportunities for indications for which an oral formulation of belinostat is relevant. As a key step in the development plan, the company has performed a canine PK bioavailability study to screen two enabling formulation technologies dedicated to improving solubility and assessed two prototypes selected based on dissolution properties, and physical and chemical stability. Findings from this study showed a good level of bioavailability approaching the theoretical maximum achievable as indicated by the performance of the oral solution. Onxeo will then select the best of the two formulation technologies, to pursue formulation development and obtain a suitable clinical prototype and, in parallel, fine tune the optimal dosing regimen to then start clinical development in selected indications. Judith Greciet, CEO of Onxeo, commented: “The positive results that we have obtained represent an important milestone towards developing a clinically-ready oral formulation of belinostat, which will provide multiple benefits to patients and physicians in terms of convenience, pain-free administration, and need for assistance from medical staff, especially as the other available PTCL treatments are injectable forms. Finally, it opens up a range of new opportunities in the orphan oncology field and beyond, giving Onxeo the opportunity to extend belinostat’s patent protection, thus reinforcing the interest to evaluate the compound in combination with other drugs for new indications.” Graham Dixon, PhD, Chief Scientific Officer of Onxeo, added: “The preclinical study conducted using the oral formulation of belinostat provides solid proof of achieving a good level of bioavailability and promising preliminary PK data. These data strongly support our next steps to conduct preclinical in vivo efficacy studies to confirm efficacy at achievable exposure levels and clinical trials with oral belinostat. ” About Onxeo Onxeo is a leading developer of orphan oncology drugs. The Company is focused on developing innovative therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo’s vision is to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, by developing advanced, effective, and safe therapeutics designed to improve the lives of patients. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with four independent programs in various stages of clinical development, including Onxeo’s first approved orphan oncology drug, Beleodaq®. The Company is headquartered in Paris, France and has approximately 50 employees. Onxeo is listed on Euronext in Paris, France (Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker: ONXEO). Onxeo’s orphan oncology products are: · Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer); and in combination with other cancer agents in first-line HCC · Beleodaq® (belinostat): FDA-approved in the US in 2014 under the agency’s accelerated approval program as a second-line treatment for patients with peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in the US, Spectrum Pharmaceuticals; belinostat in combination with other cancer agents is currently in development in first-line treatment for patients with PTCL (BelCHOP) and in other solid tumors · AsiDNA: The first-in-class siDNA (signal-interfering DNA) which has successfully undergone a proof-of-concept Phase I/IIa trial in metastatic melanoma · Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial in head and neck cancer patients with severe oral mucositis In addition, Onxeo has successfully developed and registered two non-cancer products which are currently being commercialized in the U.S. and Europe. Learn more by visiting www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http% 3 A%2F%2Fwww.onxeo.com&esheet=51354941&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=1&md5=ec87f7748ed0c5d238fe610eeb32f344). To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm a rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51354941&newsi t emid=0&lan=en -US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=7d44ce84d 8 aef4bedbd535feca9f25e0) Follow us on Twitter: @Onxeo_ Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward -looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference Document filed with the AMF on April 29, 2016, which is available on the AMF website (http://www.amf -france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww . amf-france.org&esheet=51354941&newsitemid=0&lan=en -US&anchor=http%3A%2F%2Fwww.amf -france.org&index=3&md5=52bdbf41624fcb04c97884bac6488716)) or on the company’s website (www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F w ww.onxeo.com&esheet=51354941&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=4&md5=dc81a83c0bbc689c260f5a2d3ebedea3)). Contacts Investor Relations Onxeo Nathalie Delair-Trepo, + 33 1 45 58 76 00 investors@onxeo.com or Alize RP (France) Caroline Carmagnol /Florence Portejoie, +33 6 64 18 99 59 / +33 6 47 38 90 04 onxeo@alizerp.com or The Ruth Group (U.S.) Kirsten Thomas / Lee Roth, +1 508 280 6592 / +1 646 536 7012 kthomas@theruthgroup.com / lroth@theruthgroup.com
Onxeo Announces Development of Beleodaq® Oral Formulation
Top 10 Most Recent News Articles
Mission Inn’s Lights Enter a Tender New Ownership Era
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain
Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...
Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test
Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...
Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone
Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....
Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk
A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....
Continue Reading
Australia Leads TTW's 2027 Global Travel Country List
A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...
Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays
A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...
Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal
Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...
Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue ReadingTop 5 Most Recently Viewed Articles
Exciting New Fundraising Initiative by Robin Hood for NYC
Robin Hood Introduces a New Fundraising Venture In an exciting move that demonstrates their ongoing commitment to combating poverty, Robin Hood, New York's most extensive poverty-fighting organization, has launched a unique fundraising initiative titled 'The Robin Hood Pick-A-Ticker: A Fundraiser for Robin Hood (and your Favorite Charity!).' This initiative is made...
Continue Reading
Newell Brands Faces Analyst Downgrades After Earnings Release
Newell Brands' Earnings Report: An Overview Newell Brands Inc. (NASDAQ: NWL) has recently reported its second-quarter earnings, revealing a mixed performance that has caught the attention of investors and analysts alike. Highlighting both earnings that met expectations and revenues that fell short, the company’s report has prompted analysts to adjust their projections...
Continue Reading
Smart Lock Market Projected Growth to US$ 16.47 Billion
Smart Lock Market Value and Forecast The global smart lock market is experiencing significant growth, currently valued at approximately US$ 6.76 billion in 2024. Projections indicate that it will reach US$ 16.47 billion by 2033, showcasing a robust annual growth rate (CAGR) of 10.4% during this period. This growth can be attributed to a surge in consumer awareness...
Continue Reading
Analyzing UnitedHealth Group's Current Market Movement and Outlook
Understanding the Options Activity of UnitedHealth Group In recent trading sessions, there has been notable bearish activity surrounding UnitedHealth Group (NYSE: UNH). High-profile investors seem to be indicating cautious sentiment toward this health insurance giant, which warrants the attention of retail traders. Insights from Recent Options Trading The trading data...
Continue Reading
Stan Bernard Steps Up as Zurich's New Head of Industry Practices
Stan Bernard is Promoted to Lead Industry Practices at Zurich In an exciting development for Zurich North America, Stan Bernard has been appointed as the new Head of Industry Practices for the U.S. Middle Market. This significant promotion comes as Bernard takes over from Lynn Zeitler, who is retiring after an impressive 31-year career with the company. Bernard’s ascent...
Continue Reading